Company intelligence / Profile preview

Strüngmann Group

Germany

Ownership: Private
Development stage: Other

Overview

The Strüngmann Group, run by Thomas and Andreas Strüngmann, is a family office and investment company focusing on life sciences, biotechnology, pharma, healthcare, and related sectors. It is a major investor in high-profile companies such as BioNTech, Immatics, and CorTec, among others. The Group operates through various entities including Santo Holding and Athos and is regarded as one of Europe's most prominent biotech investors, notably being the largest shareholder in BioNTech, a pioneer in mRNA-based therapeutics[1][2][3][5][6].

Industry: Investors

Partnerships

BioNTech (partnerships with Pfizer, Lilly, Sanofi, Bayer through BioNTech)[1]

Beyond the preview

Go deeper on Strüngmann Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Strüngmann Group.

Explore the full profile